The success of the contract for unilife is tied to Sanofis success in holding back generic competion to lovenox . The use of the unifill while retaing exclusivity for the class of drugs would seem to be an attempt to differentiate the product from generics on safety grounds
The following link shaows the result of a study of generic market entry on patent maedicines It can be dramatic or quite small differentiation being one of the factors . Will the syringe itself be enough to protect market share I do not know It is fascinating reading
